...
首页> 外文期刊>The Indian journal of medical research. >Weight homeostasis & its modulators in hyperthyroidism before & after treatment with carbimazole
【24h】

Weight homeostasis & its modulators in hyperthyroidism before & after treatment with carbimazole

机译:甲咪唑治疗前后甲亢的体重动态平衡及其调节剂

获取原文
获取原文并翻译 | 示例
           

摘要

Background & objectives: Hyperthyroidism is associated with increased food intake, energy expenditure and altered body composition. This study was aimed to evaluate the role of adipocytokines in weight homeostasis in patients with hyperthyroidism. Methods: Patients (n=27, 11men) with hyperthyroidism (20 Graves' disease, 7 toxic multinodular goiter) with mean age of 31.3±4.2 yr and 28 healthy age and body mass index (BMI) matched controls were studied. They underwent assessment of lean body mass (LBM) and total body fat (TBF) by dual energy X-ray absorptiometer (DXA) and blood sample was taken in the fasting state for measurement of leptin, adiponectin, ghrelin, insulin, glucose and lipids. Patients were re-evaluated after 3 months of treatment as by that time all of them achieved euthyroid state with carbimazole therapy. Results: The LBM was higher (P<0.001) in healthy controls as compared to hyperthyroid patients even after adjustment for body weight (BW), whereas total body fat was comparable between the two groups. Serum leptin levels were higher in patients with hyperthyroidism than controls (22.3±3.7 and 4.1±0.34 ng/ml, P<0.001), whereas adiponectin levels were comparable. Plasma acylated ghrelin was higher in patients than in controls (209.8±13.3 vs 106.2±8.2 pg/ml, P<0.05). Achievement of euthyroidism was associated with significant weight gain (P<0.001) and significant increase in lean body mass (P<0.001). The total body fat also increased but insignificantly from 18.4±1.8 to 19.9±1.8 kg. There was significant decrease (P<0.05) in serum leptin and acylated ghrelin but adiponectin levels remained unaltered after treatment. Serum leptin positively correlated with TBF and this correlation persisted even after adjustment for BW, BMI, gender and age (r=0.62, P=0.001). However, serum leptin and acylated ghrelin did not correlate with the presence or absence of hyperphagia. Interpretation & conclusion: Patients with hyperthyroidism predominantly had decreased lean body mass which increased after achievement of euthyroidism with carbimazole. The hyperphagia and the alterations in weight homeostasis associated with hyperthyroidism were independent of circulating leptin and ghrelin levels.
机译:背景与目的:甲状腺功能亢进症与食物摄入量增加,能量消耗增加和身体组成改变有关。本研究旨在评估脂肪细胞因子在甲状腺功能亢进症患者体重稳态中的作用。方法:研究了平均年龄为31.3±4.2岁,健康年龄与体重指数(BMI)相匹配的对照组的甲状腺功能亢进症(20例格雷夫斯病,7例中毒性多结节性甲状腺肿)患者(n = 27,11men)。他们通过双能X射线吸收仪(DXA)对瘦体重(LBM)和总脂肪(TBF)进行了评估,并在禁食状态下抽取了血液样本以测量瘦素,脂联素,生长素释放肽,胰岛素,葡萄糖和脂质。在治疗3个月后对患者进行了重新评估,因为那时他们都通过卡巴咪唑治疗达到了甲状腺功能正常。结果:即使在调整体重(BW)之后,健康对照组的LBM仍高于甲状腺机能亢进的患者(P <0.001),而两组的总体脂相当。甲状腺功能亢进症患者的血清瘦素水平高于对照组(22.3±3.7和4.1±0.34 ng / ml,P <0.001),而脂联素水平相当。患者血浆酰化生长素释放肽水平高于对照组(209.8±13.3 pg / ml和106.2±8.2 pg / ml,P <0.05)。甲状腺功能亢进症的实现与体重的显着增加(P <0.001)和瘦体重的显着增加(P <0.001)有关。体内总脂肪也从18.4±1.8 kg增加到19.9±1.8 kg,但微不足道。血清瘦素和酰化生长素释放肽水平显着降低(P <0.05),但治疗后脂联素水平保持不变。血清瘦素与TBF呈正相关,即使在调整了BW,BMI,性别和年龄之后,这种相关性仍然持续(r = 0.62,P = 0.001)。但是,血清瘦素和酰化生长素释放肽与是否有食欲亢进无关。解释与结论:甲状腺功能亢进症患者的瘦体重主要由卡咪唑引起的甲状腺功能亢进后增加。与甲状腺功能亢进有关的食欲亢进和体重动态平衡的改变与瘦素和生长素释放肽的水平无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号